Trends in adverse pregnancy outcomes among women with systemic sclerosis in the United States.
Epidemiology
Outcomes
Preeclampsia
Pregnancy
Preterm birth
Systemic sclerosis
Journal
Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
29
04
2023
revised:
31
07
2023
accepted:
03
08
2023
pubmed:
5
9
2023
medline:
5
9
2023
entrez:
4
9
2023
Statut:
ppublish
Résumé
We sought to examine temporal trends in adverse pregnancy outcomes among SSc pregnancies in a large nationwide sample. We used the National Inpatient Sample (NIS) database from 2000 - 2017 to derive national estimates of delivery-associated hospitalizations in the United States among patients with SSc. Each SSc delivery was matched to 100 non-SSc deliveries by age, delivery year, and race. We evaluated adverse pregnancy outcomes (APOs) including maternal and fetal death, cesarean delivery, hospital length of stay, preterm delivery, intrauterine growth restriction, and hypertensive disorders of pregnancy. We used multivariable regression models with an interaction term between SSc and year and adjusting for race, advanced maternal age, diabetes mellitus, and pre-existing hypertension to evaluate temporal trends in APOs among SSc and non-SSc deliveries. From 2000 to 2017, there were 3740 delivery-associated hospitalizations for women with SSc. SSc was associated with an increased risk of all APOs compared to non-SSc deliveries. Fetal death declined in SSc deliveries from 49.0 per 1000 delivery-related admissions in 2000 - 2005 to 16.2 per 1000 in 2012 - 2017. There was a significant difference in trends for fetal death between SSc and non-SSc deliveries (p = 0.043), but the trends for other APOs did not differ between the two groups. In this large nationwide sample, the risk of fetal death among women with SSc markedly improved over the past 18 years. The risk for other APOs remained high in SSc deliveries compared to non-SSc deliveries, and further studies are needed to determine what strategies can improve these outcomes.
Identifiants
pubmed: 37666113
pii: S0049-0172(23)00094-X
doi: 10.1016/j.semarthrit.2023.152252
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
152252Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest LC reports grant funding from Boerhinger Ingelheim. She has served as a consultant for Eicos Sciences, Mitsubishi Tanabe, Genentech, Gilead, Kyverna, and Jasper. All other authors report no competing interests.